Celltrion Confirms EU Bevacizumab Filing
CT-P16 Biosimilar Rival To Avastin Has Been Submitted To The EMA
Celltrion has confirmed that it has now filed its CT-P16 proposed bevacizumab rival to Avastin with the European Medicines Agency, having previously submitted it to regulators in both Korea and the US.
